|
⚲
|
| Keyboard |
| Hillhouse Capital Management Limited
✚
|
|
|---|---|
| CRD # | 295537 |
| SEC # | 801-113110 |
| CIK # | 0001510589 |
| AUM | |
| Employees | 20 (55% Investors, 0% Brokers) |
| Phone | 85221791988 |
| Address | Suite 1608, One Exchange Square Central, Hong Kong |
| Source | [IAPD] [EDGAR] |
| Total AUM ($) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Pinduoduo Inc | 0.4 | ||
| Alibaba Group Holding Ltd | 0.3 | ||
| BeiGene Ltd | 0.3 | ||
| FUTU Holdings Ltd | 0.2 | ||
| Legend Biotech Corp | 0.1 | ||
| Arrivent Biopharma Inc | 0.1 | ||
| KE Holdings Inc | 0.1 | ||
| Cytek Biosciences Inc | 0.0 | ||
| Marvell Technology Inc | 0.0 | ||
| I-Mab | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001510589] | |
| 13F-NT | [0001510589] | |
| 3 | [0001510589] | |
| 4 | [0001510589] | |
| SC 13D | [0001510589] | |
| SC 13G | [0001510589] |
| Firm Profile (Form ADV) | |
|---|---|
| Clients | 2 (100 non-US) |
| Serves | Institutional |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| ArriVent BioPharma Inc | |
| HHLR Advisors Ltd | |
| Hillhouse Investment Management Ltd | |
| BeOne Medicines Ltd | |
| Enfusion Inc | |
| Apellis Pharmaceuticals Inc | |
| China Jo-Jo Drugstores Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2025-12-10 | Sell | 555,555 | $23.37 | 12,983,320 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2024-12-02 | Sell | 17,842,500 | $200.00 | 3,568,500,000 |
|
ArriVent BioPharma Inc AVBP
Series A Preferred Stock · derivative
|
2024-01-30 | Conversion | 55,000,000 | $0.00 | |
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2024-01-30 | Conversion | 3,616,041 | ||
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2024-01-30 | Buy | 555,555 | $18.00 | 9,999,990 |
|
ArriVent BioPharma Inc AVBP
Series B Preferred Stock · derivative
|
2024-01-30 | Conversion | 4,761,903 | $0.00 | |
|
ArriVent BioPharma Inc AVBP
Common Stock
|
2024-01-30 | Conversion | 313,076 | ||
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-14 | Sell | 273,728 | $207.72 | 56,858,780 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-13 | Sell | 313,400 | $128.43 | 40,249,962 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-13 | Sell | 611,000 | $211.45 | 129,195,950 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-12 | Sell | 281,400 | $130.83 | 36,815,562 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-12 | Sell | 968,812 | $213.91 | 207,238,575 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-09 | Sell | 328,952 | $217.02 | 71,389,163 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-09 | Sell | 213,700 | $130.35 | 27,855,795 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2023-06-08 | Sell | 1,163,825 | $218.14 | 253,876,785 |
|
BeOne Medicines Ltd BGNE
Ordinary Shares
|
2022-08-22 | Other | 7,800 | $0.00 | |
|
Enfusion Inc ENFN
Class A common stock, par value $0.001 per share
|
2021-10-25 | Sell | 647,862 | $15.90 | 10,301,006 |
|
Apellis Pharmaceuticals Inc APLS
Common Stock
|
2017-11-13 | Conversion | 2,098,581 | ||
|
Apellis Pharmaceuticals Inc APLS
Series D Convertible Preferred Stock · derivative
|
2017-11-13 | Conversion | 4,476,275 | $0.00 | |
|
Apellis Pharmaceuticals Inc APLS
Common Stock
|
2017-11-13 | Buy | 1,428,571 | $14.00 | 19,999,994 |
| showing 20 of 24 most recent transactions | |||||